Abstract
ObjectivesAutoimmune polyglandular syndrome type‐1 (APS‐1) is a monogenic recessive disorder characterised by multiple endocrine abnormalities, chronic mucocutaneous candidiasis and high titres of serum autoantibodies. To date, no curative treatment is available; current therapies manage the symptoms rather than treating the cause and have major side effects. APS‐1 is caused by mutations in the autoimmune regulator (AIRE) gene. AIRE mediates central tolerance by directing the ectopic expression of tissue‐specific antigens (TSAs) in medullary thymic epithelial cells, causing the deletion of self‐reactive thymocytes. Therefore, loss‐of‐function mutations in AIRE result in a multisystem autoimmune disease. Because of the monogenic aetiology of APS‐1 and availability of an APS‐1 mouse model, we have explored the option of restoring functional AIRE using adeno‐associated virus serotype 9 (AAV9).MethodsThe efficacy of AAV9‐AIRE (AAV9 carrying AIRE cDNA) gene therapy was assessed in an APS‐1 mouse model. We performed intrathymic injection of AAV9‐AIRE into APS‐1 mouse model using ultrasound imaging technique to accurately locating the thymus. We evaluated the efficiency of this approach alongside measures of autoimmunity and histology of target tissues.ResultsIntrathymic injection of AAV9‐AIRE demonstrated high transduction efficiency and restored AIRE expression in the thymus. AIRE gene delivery led to a significant increase in TSA expression, and importantly a significant reduction of serum autoantibodies in treated versus control mice, which fell to near‐undetectable levels by 4 weeks post‐treatment. Furthermore, histological analysis of treated animals showed near‐normal tissue morphology with no lymphocytic infiltrations, a hallmark of untreated Aire‐deficient mice.ConclusionThis study has demonstrated the feasibility of AAV9‐AIRE as a vehicle for gene therapy for APS‐1.
Highlights
Autoimmune polyglandular syndrome type 1(APS-1) known as autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is an incurable monogenic autosomal recessive disorder[1] classed as a primary immunodeficiency disease (PID)
Because of the monogenic aetiology of Autoimmune polyglandular syndrome type-1 (APS-1) and availability of an APS-1 mouse model, we have explored the option of restoring functional autoimmune regulator (AIRE) using adeno-associated virus serotype 9 (AAV9)
Our study revealed that gene delivery using AAV9 vectors (AAV9-AIRE) into mouse thymus led to a profound amelioration of the APS-1 phenotype in AireÀ/À mice
Summary
(APS-1) known as autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is an incurable monogenic autosomal recessive disorder[1] classed as a primary immunodeficiency disease (PID). It is characterised by the manifestations of both endocrine and nonendocrine organ destruction.[1,2] Typically, the initial presentation is with chronic mucocutaneous candidiasis (CMC), followed by hypoparathyroidism and adrenal insufficiency (Addison’s disease).[1,2] Serum from. Autoantibodies to thyroid were detected in APS-1 patients with hypothyroid who were seropositive to thyroglobulin (TG) and thyroid peroxidase (TPO).[5] autoantibodies against
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
